SERDEMETAN

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H20N4
Molecular Weight	328.4103
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CC1=CNC2=C1C=CC=C2)NC3=CC=C(NC4=CC=NC=C4)C=C3

InChI

InChIKey=CEGSUKYESLWKJP-UHFFFAOYSA-N

InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)

HIDE SMILES / InChI

Molecular Formula	C21H20N4
Molecular Weight	328.4103
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21922647
Curator's Comment: Description was created based on several sources, including http://www.eurodiagnostico.com/media/pdf/JNJ%2026854165%20(Serdemetan).pdf http://adisinsight.springer.com/drugs/800014298

JNJ-26854165 (Serdemetan), a novel tryptamine derivative, was developed as an activator of p53, and its initially proposed mechanism of action involved preventing the association of HDM2 with the proteasome and thereby stabilizing HDM2 substrates such as p53. Consistent with this proposed mechanism, Serdemetan induced apoptosis in acute myeloid and lymphoid leukemia cell lines and in primary acute leukemia isolates. Serdemetan is currently being evaluated in Phase I clinical trials in patients with non-small cell lung cancer; prostate cancer; solid tumours.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
p53-binding protein Mdm-2 9 Target ID: CHEMBL5023 Sources: http://www.eurodiagnostico.com/media/pdf/JNJ%2026854165%20(Serdemetan).pdf	Antagonist 2849
NALM-6 1 Target ID: CHEMBL614187 Sources: http://www.eurodiagnostico.com/media/pdf/JNJ%2026854165%20(Serdemetan).pdf	Inhibitor 8504	0.32 µM [IC50]
REH 1 Target ID: CHEMBL2366320 Sources: http://www.eurodiagnostico.com/media/pdf/JNJ%2026854165%20(Serdemetan).pdf	Inhibitor 8504	0.44 µM [IC50]
Cellular tumor antigen p53 21 Target ID: CHEMBL4096 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27999193 \| https://www.ncbi.nlm.nih.gov/pubmed/21922647	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: https://clinicaltrials.gov/ct2/show/NCT00676910	Primary		Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
2330 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21831953	350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered:		SERDEMETAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
43 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21831953	350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered:		SERDEMETAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
16 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21831953	350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered:		SERDEMETAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=363677242	yes [IC50 0.4772 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=363677242	yes [IC50 2.6837 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=363677242	yes [IC50 3.7908 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/27116025/

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY114771	https://www.001chemical.com/chem/search?q=DY114771
1PlusChem LLC	1P008CTZ	https://www.1pchem.com/search?query=1P008CTZ
AChemBlock	O33888	http://www.achemblock.com/catalogsearch/result/?q=O33888
Achemo Scientific Limited	AC-95357	http://www.achemo.com/search/?Keyword=AC-95357
AK Scientific	X7539	https://aksci.com/item_detail.php?cat=X7539
Angene	AGN-PC-0WH8JD	http://www.angenechemical.com/productshow/AGN-PC-0WH8JD.html
AOBIOUS INC	AOB87702	http://aobious.com/aobious/search?search_query=AOB87702
ApexBio Technology	A4204	https://www.apexbt.com/catalogsearch/result/?q=A4204
Axon MedChem	1538	https://www.axonmedchem.com/product/1538
Axon MedChem	1586	https://www.axonmedchem.com/product/1586
Cayman Chemical	16259	http://www.caymanchem.com/app/template/Product.vm/catalog/16259
Chem Scene	CS-0166	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0166
ChemShuttle	106213	https://www.chemshuttle.com/catalogsearch/result/?q=106213
Combi-Blocks	QJ-2614	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-2614
eMolecules	32176499	https://orderbb.emolecules.com/search/#?query=32176499
eMolecules	84830266	https://orderbb.emolecules.com/search/#?query=84830266
eNovation Chemicals	D372313	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372313&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A267	http://www.excenen.com/searchresultlist.php?id=EX-A267
KeyOrganics	AS-56263	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56263
Lab Network	LN00199398	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00199398
Matrix Scientific	96765	http://www.matrixscientific.com/096765.html
mcule	MCULE-3208909455	https://mcule.com/MCULE-3208909455/
MedChem Express	HY-12025	https://www.medchemexpress.com/search.html?q=HY-12025&ft=&fa=&fp=
Molcore	MC114771	http://www.molcore.com/CatMC114771.html
Molnova	M16390	https://www.molnova.com/en/serch-list.html?keywords=M16390
MolPort	MolPort-009-679-468	https://www.molport.com/shop/molecule-link/MolPort-009-679-468
MolPort	MolPort-042-665-719	https://www.molport.com/shop/molecule-link/MolPort-042-665-719
MuseChem	I005297	https://www.musechem.com/product/I005297.html
PI Chemicals	PI-38506	http://www.pipharm.com/catalog_products/PI-38506.html
Ryan Scientific	GSK2578215A	https://ryansci.com/products?q=GSK2578215A&list_q=&search_type=exact
ShangHai Biochempartner	BCP000255	http://www.biochempartner.com/search_BCP000255
ShangHai Biochempartner	BCP02124	http://www.biochempartner.com/search_BCP02124
Toronto Research Chemicals	J211343	https://www.trc-canada.com/product-detail/?CatNum=J211343
W&J PharmaChem	50C1554821	http://wjpharmachem.com/new/searcht.php?keyword=50C1554821

PubMed

Title	Date	PubMed
The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.	2013-09	23820125
Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes.	2013	24040331

Patents

Sample Use Guides

In Vivo Use Guide

The maximum tolerated dose (MTD) of serdemetan was determined to be 350 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

Serdemetan induced a dose-dependent inhibition of proliferation in both wild-type (wt) and mutant (mut) p53 cell lines, with IC50 values from 0.25 to 3 uM/L, in association with an S phase cell cycle arrest.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:43:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:43:08 GMT 2025`
Record UNII	ID6YB4W3V8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

JNJ-26854165

Preferred Name

English

SERDEMETAN

Official Name

English

Serdemetan [WHO-DD]

Common Name

English

N-(2-(1H-INDOL-3-YL)ETHYL)-N'-(PYRIDIN-4-YL)BENZENE-1,4-DIAMINE

Systematic Name

English

serdemetan [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129839